Showing 3891-3900 of 4165 results for "".
- US Eye Adds New Partnerships in Virginia, North Carolina, South Carolina, and Floridahttps://modernod.com/news/us-eye-adds-new-partnerships-in-virginia-north-carolina-south-carolina-and-florida/2480301/The US Eye practice network has recently expanded its practice base to 50 clinics and five surgery centers across the southeastern United States. Financial terms of the deal were not disclosed. US Eye has partnered with Griffey Eye Care located in Chesapeake, Virginia; Al
- Nicox Does Not Meet Primary or Secondary Endpoints in Phase 2b Mississippi Blepharitis Trialhttps://modernod.com/news/nicox-does-not-meet-primary-or-secondary-endpoint-in-phase-2b-mississippi-blepharitis-trial/2480300/Nicox SA announced the results from its Mississippi phase 2b clinical trial evaluating once-daily dosed NCX 4251, fluticasone propionate ophthalmic suspension 0.1%, against placebo in patients with acute exacerbations o
- FYidoctors Makes Expansion into US Markethttps://modernod.com/news/fyidoctors-makes-expansion-into-us-market/2480296/Canadian eye care provider FYidoctors announced that it has expanded its geographic operations into the US marketplace with the addition of six leading eye care clinics throughout the state of California. The foray marks a major company milestone as the first time FYidoctors has ad
- Gemini Therapeutics Announces Data from Its Ongoing Phase 2a Study of GEM103 at EURETINA 2021https://modernod.com/news/gemini-therapeutics-announces-data-from-its-ongoing-phase-2a-study-of-gem103-at-euretina-2021/2479579/Gemini Therapeutics announced that Raj Maturi, MD, Adjunct Clinical Assistant Professor of Ophthalmology at Indiana University School of Medicine and an investigator in the ReGAtta study, presented Gemini’s previously released initial results from its ongoing phase 2a study at EURETINA 2021
- Samsung Bioepis Announces Results From Post-Hoc Analysis of Phase 3 Study of Ranibizumab Biosimilar Byoovizhttps://modernod.com/news/samsung-bioepis-announces-results-from-post-hoc-analysis-of-phase-3-study-of-ranibizumab-biosimilar-byooviz/2479497/Samsung Bioepis announced results from a post-hoc and subgroup analysis of phase 3 clinical study of Byooviz (ranibizumab biosimilar) identifying the baseline factors associated with visual acuity and anatomical outcomes at both primary endpoints through week 52. The study results will be present
- AMA: Look to Ophthalmology for a Glimpse of Telemedicine’s Futurehttps://modernod.com/news/ama-look-to-ophthalmology-for-a-glimpse-of-telemedicines-future/2479477/Early on in the COVID-19 pandemic, ophthalmology struggled to adapt to telemedicine. It just wasn’t set up for virtual visits. “Ophthalmology is an exam-heavy specialty, and we really rely on all the clinical clues that we capture—either at the slit lamp, or looking at the retina, or check
- Santen and Sydnexis Execute an Exclusive Licensing Agreement for SYD-101, an Investigational Treatment for Progressive Childhood Myopiahttps://modernod.com/news/santen-and-sydnexis-execute-an-exclusive-licensing-agreement-for-syd-101-a-novel-investigational-treatment-for-progressive-childhood-myopia/2479443/Santen and Sydnexis have signed an exclusive licensing agreement for SYD-101, Sydnexis’ investigational proprietary low-dose atropine formulation for childhood myopia, for Europe, the Middle East, and Africa (EMEA). SYD-101 is currently undergoing a large multicenter phase 3 clinical trial, the S
- Outlook Therapeutics Reports Positive Efficacy and Safety Data from Phase 3 NORSE TWO Trial of Lytenava for Wet AMDhttps://modernod.com/news/outlook-therapeutics-reports-positive-efficacy-and-safety-data-from-phase-3-norse-two-trial-of-lytenava-for-wet-amd/2479428/Outlook Therapeutics announced positive clinical and highly statistically significant topline results from its pivotal phase 3 NORSE TWO safety and efficacy trial evaluating ONS-5010/Lytenava (bevacizumab) for treatment of neovascular age-related macular degeneration (wet AMD). “We are de
- EyePoint Pharmaceuticals Forms Executive Scientific Advisory Boardhttps://modernod.com/news/eyepoint-pharmaceuticals-forms-executive-scientific-advisory-board/2479426/EyePoint Pharmaceuticals announced the formation of its Executive Scientific Advisory Board (SAB), chaired by Carl Regillo MD, FACS, Chief of the Retina Service at Wills Eye Hospital. Other members of the SAB include Sophie J. Bakri, MD, Mayo Clinic; Caroline R. B
- Ocular Therapeutix Announces First Patient Dosed in US-Based Phase 1 Trial of OTX-TKI for Wet AMDhttps://modernod.com/news/ocular-therapeutix-announces-first-patient-dosed-in-us-based-phase-1-clinical-trial-of-otx-tki-for-the-treatment-of-wet-amd/2479421/Ocular Therapeutix announced that it has dosed the first patient in the United States phase 1 clinical trial of OTX-TKI (axitinib intravitreal implant) for the treatment of wet age-related macular degeneration (AMD). “We are very excited to have recently begu